Teladoc Health’s (TDOC) Hold Rating Reiterated at Needham & Company LLC

Teladoc Health (NYSE:TDOC)‘s stock had its “hold” rating reaffirmed by investment analysts at Needham & Company LLC in a report released on Friday, Benzinga reports.

TDOC has been the subject of several other research reports. Canaccord Genuity Group lowered their price objective on Teladoc Health from $34.00 to $28.00 and set a “buy” rating for the company in a research report on Wednesday, February 21st. Truist Financial lowered their price objective on Teladoc Health from $23.00 to $17.00 and set a “hold” rating for the company in a research report on Wednesday, March 6th. SVB Leerink began coverage on Teladoc Health in a research report on Monday, February 26th. They set a “market perform” rating and a $17.00 price objective for the company. Piper Sandler lowered their price target on Teladoc Health from $30.00 to $25.00 and set an “overweight” rating for the company in a research report on Wednesday, February 21st. Finally, Cantor Fitzgerald began coverage on Teladoc Health in a research report on Thursday, February 29th. They issued an “overweight” rating and a $22.00 price target for the company. Eight analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $22.23.

Teladoc Health Stock Performance

NYSE:TDOC opened at $13.33 on Friday. The stock has a market cap of $2.26 billion, a P/E ratio of -9.95 and a beta of 0.94. The firm’s fifty day simple moving average is $15.17 and its 200 day simple moving average is $17.80. Teladoc Health has a twelve month low of $12.85 and a twelve month high of $30.41. The company has a quick ratio of 3.47, a current ratio of 3.54 and a debt-to-equity ratio of 0.66.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings results on Thursday, April 25th. The health services provider reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.02). The company had revenue of $646.13 million during the quarter, compared to the consensus estimate of $637.31 million. Teladoc Health had a negative net margin of 8.47% and a negative return on equity of 9.22%. The business’s revenue was up 2.7% on a year-over-year basis. During the same quarter last year, the firm earned ($0.37) EPS. As a group, research analysts predict that Teladoc Health will post -1.07 EPS for the current year.

Insider Activity at Teladoc Health

In other Teladoc Health news, CAO Richard J. Napolitano sold 3,765 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $14.52, for a total value of $54,667.80. Following the completion of the transaction, the chief accounting officer now directly owns 18,077 shares in the company, valued at approximately $262,478.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CAO Richard J. Napolitano sold 3,765 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $14.52, for a total transaction of $54,667.80. Following the sale, the chief accounting officer now directly owns 18,077 shares of the company’s stock, valued at approximately $262,478.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CMO Stephany Verstraete sold 7,945 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $14.52, for a total value of $115,361.40. Following the sale, the chief marketing officer now directly owns 56,486 shares in the company, valued at $820,176.72. The disclosure for this sale can be found here. In the last ninety days, insiders sold 135,441 shares of company stock worth $2,038,251. 1.63% of the stock is owned by company insiders.

Institutional Trading of Teladoc Health

Several hedge funds have recently modified their holdings of the company. ICA Group Wealth Management LLC purchased a new stake in Teladoc Health during the 4th quarter valued at $28,000. Hexagon Capital Partners LLC grew its position in Teladoc Health by 204.4% in the 4th quarter. Hexagon Capital Partners LLC now owns 1,586 shares of the health services provider’s stock valued at $34,000 after acquiring an additional 1,065 shares during the last quarter. RIA Advisory Group LLC bought a new position in Teladoc Health in the 4th quarter valued at $36,000. GAMMA Investing LLC bought a new position in Teladoc Health in the 4th quarter valued at $41,000. Finally, Principal Securities Inc. bought a new position in Teladoc Health in the 4th quarter valued at $45,000. 76.82% of the stock is owned by hedge funds and other institutional investors.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.